INmune Bio (INmune Bio) FCF Yield % : -8.83 (As of May. 15, 2024)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, INmune Bio's Trailing 12-Month Free Cash Flow is $-18.32 Mil, and Market Cap is $224.73 Mil. Therefore, INmune Bio's FCF Yield % for today is -8.83%.

The historical rank and industry rank for INmune Bio's FCF Yield % or its related term are showing as below:

INMB' s FCF Yield % Range Over the Past 10 Years
Min: -26.56 Med: -10.1 Max: -2.68
Current: -8.83

During the past 8 years, the highest FCF Yield % of INmune Bio was -2.68%. The lowest was -26.56%. And the median was -10.10%.

INMB's FCF Yield % is ranked better than
59.85% of 1554 companies
in the Biotechnology industry
Industry Median: -14.48 vs INMB: -8.83

INmune Bio's FCF Margin % for the quarter that ended in Mar. 2024 was -53,400.00%.

INmune Bio FCF Yield % Historical Data

The historical data trend for INmune Bio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio FCF Yield % Chart

INmune Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-8.62

-3.85

-23.90

-19.94

-5.93

INmune Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-3.94	-7.79	-13.98	-6.73	-14.18

Competitive Comparison of INmune Bio's FCF Yield %

For the Biotechnology subindustry, INmune Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where INmune Bio's FCF Yield % falls into.

INmune Bio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

INmune Bio's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-11.98	/	202.126008
	=	-5.93%

INmune Bio's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-7.476	*	4	/	210.9219
	=	-14.18%

INmune Bio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

INmune Bio FCF Yield % Related Terms

Thank you for viewing the detailed overview of INmune Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

INmune Bio (INmune Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Executives

Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016